According to the Surveillance, Epidemiology, and End Results (SEER) registry, the survival outcomes of HR+/HER2+ BC fall between those of HR+/HER2− and HR−/HER2+ subtypes, suggesting an intermediate prognosis [5]. The gene discussed is HR; the disease is breast cancer.